Acerta Pharma

Developing the leading second-generation BTK inhibitor

Acerta is developing the leading second-generation BTK inhibitor for the treatment of hematologic malignancies and severe diseases of inflammation. The company has operations in Oss, the Netherlands and multiple U.S. sites. Its U.S. headquarters is in Redwood City, CA. Acerta was acquired by AstraZeneca in 2016.

Status
Acquired by AstraZeneca in 2016
Year of Investment
2013
Strategy
Life Sciences
Location
The Netherlands